Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD Study of ABL301 in Healthy Adults
NCT05756920Phase 1Completed
- Sponsor
- ABL Bio
- Start
- Dec 2022
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Parkinson's disease (PD) comparing ABL301 with Placebo (2 arms). Primary endpoint: Incidence of Treatment-Emergent Adverse Events. Started Dec 2022; status: completed.
02
Drugs
ABL301
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT05756920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05756920.